Watch TXG. Know when insiders buy.
One email the day a filing lands. Free.
TXG
10x Genomics, Inc.
75.59
+4.13 +5.78%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
36
FLAG · insiders 25, shorts 46
Insiders, 90 days
−$10.7M
net selling · 0 buys, 24 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.7BP/E —DIV YIELD —FCF YIELD 1.26%REV TTM $616.9M −4.3%NET INCOME −$75.1MNET CASH $314.3M52W 12.26 – 97.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $151M | −12.6% | 74.5% | −$19.6M | −$17.9M | −151.9% | -0.14 | $17M | $1.6M | $15.4M | Aug 7 |
| Q1 2026 · Mar 31 | $150.8M | −2.6% | 70.4% | −$17M | −$13.5M | — | -0.10 | $26.1M | $1.6M | $24.5M | Aug 7 |
| Q4 2025 · Dec 31derived | $166M | +0.6% | 68.1% | −$19.5M | −$16.3M | — | -0.13 | $40.8M | $1.8M | $39M | Feb 13 |
| Q3 2025 · Sep 30 | $149M | −1.7% | 67.3% | −$32.2M | −$27.5M | — | -0.22 | $43.2M | $687K | $42.5M | Nov 7 |
| Q2 2025 · Jun 30 | $172.9M | +12.9% | 72.3% | $30.1M | $34.5M | — | 0.28 | $17.7M | $1.6M | $16.1M | Aug 7 |
| Q1 2025 · Mar 31 | $154.9M | +9.8% | 68.1% | −$39.3M | −$34.4M | — | -0.28 | $34.4M | $1.9M | $32.5M | Aug 7 |
| Q4 2024 · Dec 31derived | $165M | −10.3% | 67.2% | −$49.8M | −$49M | — | -0.41 | −$6.7M | $2.7M | −$9.5M | Feb 13 |
| Q3 2024 · Sep 30 | $151.7M | −1.3% | 70.2% | −$41.5M | −$35.8M | — | -0.30 | $21.6M | $3.9M | $17.8M | Nov 7 |
| Q2 2024 · Jun 30 | $153.1M | — | 68.1% | −$41.7M | −$37.9M | — | -0.32 | $7.5M | $2.9M | $4.6M | Nov 7 |
| Q1 2024 · Mar 31 | $141M | — | 65.9% | −$61.5M | −$59.9M | — | -0.50 | −$15.7M | $2.9M | −$18.6M | Nov 7 |
| Q4 2023 · Dec 31derived | $184M | — | 62.9% | −$55.2M | −$49M | — | -0.41 | $25.8M | $3.5M | $22.3M | Feb 13 |
| Q3 2023 · Sep 30 | $153.6M | — | 62.2% | −$94.8M | −$93M | — | -0.79 | −$25.3M | $15.2M | −$40.5M | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $642.8M | 69.1% | −$61M | −$43.5M | -6.8% | -0.35 | $136.1M | $5.9M | $130.1M | — | — |
| FY2024 · to Dec 31 | $610.8M | 67.9% | −$194.6M | −$182.6M | -29.9% | -1.52 | $6.7M | $12.4M | −$5.7M | — | — |
| FY2023 · to Dec 31 | $618.7M | 66.2% | −$265.3M | −$255.1M | -41.2% | -2.18 | −$15.2M | $48.6M | −$63.8M | — | — |
| FY2022 · to Dec 31 | $516.4M | 76.7% | −$167.9M | −$166M | -32.1% | -1.46 | −$33.6M | $131.7M | −$165.3M | — | — |
| FY2021 · to Dec 31 | $490.5M | 84.9% | −$52.3M | −$58.2M | -11.9% | -0.53 | −$21.4M | $101.3M | −$122.7M | — | — |
| FY2020 · to Dec 31 | $298.8M | 80.4% | −$534.1M | −$542.7M | -181.6% | -5.37 | −$217.9M | $36.7M | −$254.6M | — | — |
Every number comes from 10x Genomics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.